Income Statement
ONKURE THERAPEUTICS, INC.
OKUR
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Revenue
|
- | - | - | - | - |
|
Cost of Revenue
|
- | - | - | - | - |
|
Gross Profit
|
- | - | - | - | - |
|
Operating Expenses
|
62.95 | 54.39 | 83.05 | 53.85 | 39.82 |
|
Research & Development
|
48.26 | 43.80 | 56.61 | 37.71 | 28.17 |
|
Selling, General & Administrative
|
14.69 | 10.59 | 26.44 | 16.14 | 11.65 |
|
Other Operating Expenses
|
- | - | - | - | - |
|
Operating Income
|
-62.95 | -54.39 | -83.05 | -53.85 | -39.82 |
|
Non-Operating Income
|
- | - | - | - | - |
|
Interest Income
|
3.44 | 2.01 | - | - | - |
|
Interest Expense
|
- | - | - | - | - |
|
Other Non-Op Income / Expense
|
- | - | 5.67 | 1.89 | - |
|
Income Before Tax
|
- | - | -77.39 | -51.96 | -39.77 |
|
Income Tax Expense
|
- | - | - | - | - |
|
Non-Controlling Interest
|
- | - | - | - | - |
|
Net Income
|
-59.52 | -52.67 | -77.39 | -51.96 | -39.77 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - |
|
EBITDA
|
-62.50 | -53.93 | -82.88 | -53.76 | -39.77 |
|
Earnings Per Share (Basic)
|
-4.40 | -15.28 | -2.52 | -2.12 | -2.19 |
|
Diluted EPS
|
-4.40 | -15.28 | -2.52 | -2.12 | -2.19 |
|
Weighted Average Shares
|
13.52 | 3.45 | 30.68 | 24.50 | 18.14 |
|
Diluted Weighted Avg Shares
|
13.52 | 3.45 | 30.68 | 24.50 | 18.14 |
|
Comprehensive Income
|
- | - | -77.34 | -52.03 | -39.74 |